Skip to main content
TipRanks
Go Ultimate75% OFF

Olema Pharmaceuticals (OLMA) Stock Price & Analysis

1,019 Followers

OLMA Stock Chart & Stats

$7.22-$0.14(-1.90%)
At close: 4:00 PM EST
$7.5$10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$7.02 - $7.50
52-Week Range
$6.24 - $36.26
Previous Close
$7.36
Volume
N/A
Average Volume (3M)
1.41M
Market Cap
$644.78M
Enterprise Value
$463.03M
Total Cash (Recent Filing)
$413.77M
Total Debt (Recent Filing)
$3.36M
Price to Earnings (P/E)
―
Beta
1.07
Next Earnings
Mar 23, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Minimal debt relative to equity gives Olema a conservative capital structure and avoids a major fixed financing burden while it funds clinical development. This provides flexibility around capital allocation, although it does not remove the need to finance continuing losses.

Late-stage Oncology Pipeline

Palazestrant is being advanced in two pivotal Phase 3 trials, with OPERA-01 data expected in the first quarter of 2027 and OPERA-02 enrollment accelerating. This late-stage focus creates a defined path toward potential regulatory and commercial milestones.

Experienced Finance Leadership

Hiring a veteran biotech finance executive strengthens leadership capacity as Olema approaches pivotal data and a potential first commercial launch. His remit over capital markets and financial strategy is relevant to managing the company’s transition and funding needs.

Bears Say

No Operating Revenue

The absence of revenue confirms that Olema remains pre-commercial and dependent on clinical progress before it can establish an operating business. Until a product is approved and launched, financial performance will remain driven primarily by development spending rather than customer demand.

Widening Losses

Losses have widened materially over time, indicating that the cost base is expanding faster than any emerging operating contribution. Persistently negative operating results reduce internal funding capacity and increase the financial importance of successful clinical development and eventual commercialization.

Heavy Cash Burn

Sustained negative operating and free cash flow means Olema is consuming substantial capital to fund its programs rather than generating cash internally. This raises ongoing financing dependence and can reduce financial flexibility if development costs remain elevated or milestones take longer.

Olema Pharmaceuticals News

OLMA FAQ

What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $6.24 and its highest was $36.26 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Olema Pharmaceuticals’s market cap is $644.78M.
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s next earnings report is estimated for Mar 23, 2027 (not yet confirmed), which is in 125 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on Nov 10, 2026. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.637 by -$0.093.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -0.76.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 87,606,260 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.637. Following the earnings report the stock price went down -1.223%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Hedge funds hold Olema Pharmaceuticals shares: the largest hedge-fund position in Olema Pharmaceuticals is 72,326,020 shares, and hedge funds decreased their holdings by 2.3M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology